Recursion Pharmaceuticals Inc (RXRX) Stock Price Today
Aura AI Summary
Key Stats
- $2.00BMarket Cap
- 16,719,541Volume
- HealthSector
- $4.9652W High
- $2.8452W Low
- 23 DaysTypical Hold Time
- $1.52BEnterprise Value
- -Div Yield
- 0% Sell | 100% BuyTrading Activity
Track Recursion Pharmaceuticals Inc (RXRX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Recursion Pharmaceuticals Inc has traded between a low of $2.84 and a high of $4.96, highlighting its annual price range. Buy and sell Recursion Pharmaceuticals Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Most Recent News
Dassault Systèmes targets double-digit revenue and EPS growth by 2029 with AI-driven industrial solutions.
Dassault Systèmes announced at its 2026 Capital Markets Day a new growth cycle aiming for double-digit revenue and EPS growth by 2029, targeting over €8 billion in revenue and €1.80 in non-IFRS diluted EPS. The company highlights its transition to su...

SBM Offshore wins contract to build and operate Longtail FPSO in Guyana for 10 years
SBM Offshore has secured contracts from ExxonMobil Guyana to construct and operate a Floating Production, Storage and Offloading vessel (FPSO) for the Longtail development in Guyana's Stabroek Block. The FPSO will process 1.2 billion cubic feet of ga...

Agilon Health rated HOLD with 14.6% downside risk amid uncertain earnings and contract risks.
Agilon Health is rated HOLD with a 12-month price target of $98, which is 14.6% below its recent closing price of $114.81. The company’s margin upgrade for 2026 was driven by rising patient risk scores, especially in Ohio and Texas ACOs, but the sust...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.